基化酶-5抑制对系统性右静脉管的大小和功能的影响. 一个多中心,双盲,随机,安慰剂对照试验:服务
Matthias Greutmann1, Daniel Tobler2, Reto Engel3
1University Heart Center, Department of cardiology, University of Zurich, Zürich, Switzerland.
European journal of heart failure
|June 2, 2023
概括
塔达拉菲尔在患有全身右心室的成年人中,在三年内没有改善右心室缩功能. 这项研究发现,在治疗塔达拉菲尔时,心脏功能或运动能力没有显著变化.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有先天性心脏病和全身右心室的成年人经常经历渐进的右心室缩功能障碍,导致不良后果.
- 识别有效的治疗方法来改善这群人群的右心室功能至关重要.
研究的目的:
- 评估代酶-5抑制剂塔达拉菲尔对右心室缩功能的影响,对有系统右心室的成年人进行评估.
主要方法:
- 一个双盲,随机,安慰剂控制的优越性试验,涉及100名右心室全身性成年人.
- 患者每天接受一次20毫克的达拉菲尔或安慰剂3年.
- 主要终点:右心室末缩体积的变化;次要终点:右心室喷射分数,运动能力和N端亲B型尿素水平.
主要成果:
- 在3年内,无论是tadalafil还是安慰剂组,都没有观察到右心室末缩体积的显著变化.
- 在tadalafil和安慰剂组之间没有发现主要终点的显著差异 (p=0.39).
- 二级终点,包括右心室喷射率和运动能力,也显示没有显著的变化或群体之间的差异.
结论:
- 在有系统右心室的成年人中,在3年的随访期间,塔达拉菲尔没有显著改善右心室缩功能,运动能力或神经激素激活.
- 这项研究表明,在这个患者群体中,塔达拉菲尔不是改善心室功能的有效治疗方法.
- 需要进一步的研究,以确定有效的治疗策略,以增强有系统右心室的成年人心室功能.
更多相关视频
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
199
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
199
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:22Mitral Stenosis I: Introduction
19
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
19
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
471
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
471